The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prevalence of incidental germline pathogenic (PV) and likely pathogenic (LPV) variants in hereditary cancer-related genes identified in matched tumor/normal sequencing of advanced solid tumors.
 
Ecaterina Elena Ileana Dumbrava
No Relationships to Disclose
 
Lauren Brusco
No Relationships to Disclose
 
Molly S Daniels
No Relationships to Disclose
 
Chetna Wathoo
No Relationships to Disclose
 
Kenna Rael Shaw
No Relationships to Disclose
 
Karen H. Lu
No Relationships to Disclose
 
Xiaofeng Zheng
No Relationships to Disclose
 
Louise C. Strong
No Relationships to Disclose
 
Jennifer Keating Litton
Consulting or Advisory Role - Medivation; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Genentech; medivation; Novartis; pfizer
Patents, Royalties, Other Intellectual Property - UptoDate
Travel, Accommodations, Expenses - Medivation
 
Banu Arun
Consulting or Advisory Role - Abbvie
 
Agda Karina Eterovic
No Relationships to Disclose
 
Mark Routbort
No Relationships to Disclose
 
Sarina Anne Piha-Paul
Research Funding - Abbvie; Cerulean Pharma; Curis; GlaxoSmithKline; Helix BioPharma; Incyte; Medivation; Merck Sharp & Dohme; Novartis; Principa Biopharma; Puma Biotechnology; Roche; XuanZhu
 
Vivek Subbiah
Research Funding - Novartis, GSK, Nanocarrier, NorthWest Biotherapeutics, Roche/Genentech, BergPharma, Bayer, Incyte, FujiFilm, Pharmamar, D3, Pfizer Amgen, Abbvie, Multivir, Bluprint Medicines.
Travel, Accommodations, Expenses - Novartis, Pharmamar, Fujifilm
 
David S. Hong
Stock and Other Ownership Interests - MolecularMatch; Oncorena
Honoraria - Adaptimmune; Baxter; Bayer; Merrimack
Consulting or Advisory Role - Baxter; Bayer
Research Funding - Amgen; AstraZeneca; Daiichi Sankyo; Eisai; Genentech; Lilly; Merck; Mirati Therapeutics; miRNA Therapeutics; Novartis; Pfizer
Travel, Accommodations, Expenses - Loxo; miRNA Therapeutics
Other Relationship - Oncorena
 
Scott Kopetz
Stock and Other Ownership Interests - MolecularMatch
Consulting or Advisory Role - Amgen; Array BioPharma; Bayer; Genentech; Merrimack; MolecularMatch; Roche; Sanofi; Taiho Pharmaceutical
Research Funding - Amgen (Inst); Array BioPharma (Inst); Biocartis (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Guardant Health (Inst); MedImmune (Inst); Novartis (Inst); Sanofi (Inst)
 
John Mendelsohn
Leadership - Merrimack
Patents, Royalties, Other Intellectual Property - ImClone Systems; U Cal San Diego
 
Gordon B. Mills
Stock and Other Ownership Interests - Catena; Immunome; Myriad Genetics; PTV Sciences; Spindletop Ventures
Honoraria - Allostery; AstraZeneca; Immunome; Isis Pharmaceuticals; Lilly; Novartis; Nuevolution; Symphony Evolution
Consulting or Advisory Role - Adventis Health; Allostery; AstraZeneca; Catena; Critical Outcome Technologies; Isis Pharmaceuticals; Lilly; MedImmune; Millennium; Novartis; Nuevolution; Precision Medicine Research Associates, LLC; Provista Diagnostics; SignalChem; Symphony Evolution; Tarveda Therapeutics; Tau Therapeutics
Research Funding - Adelson Medical Research Foundation; AstraZeneca; Breast Cancer Research Foundation; Critical Outcome Technologies; Illumina; Karus Therapeutics; Komipharm; Millennium; NanoString Technologies
Patents, Royalties, Other Intellectual Property - HRD assay to Myriad Genetics
Travel, Accommodations, Expenses - Allostery; AstraZeneca; Immunome; Isis Pharmaceuticals; Lilly; MedImmune; Novartis; Pfizer; Symphony Evolution
 
Ken Chen
No Relationships to Disclose
 
Funda Meric-Bernstam
Honoraria - Genentech; Roche
Consulting or Advisory Role - Celgene; Clearlight Diagnostics; Genentech; Inflection Biosciences; Novartis; Pieris Pharmaceuticals; Roche
Research Funding - Aileron Therapeutics; AstraZeneca; Bayer; Calithera Biosciences; Curis; CytomX Therapeutics; Debiopharm Group; Effective Pharmaceuticals; Genentech; Jounce Therapeutics; Novartis; PUMA Biotechnology; Taiho Pharmaceutical; Verastem; Zymeworks